Translational Impact & IP Output

Scholarly Portfolio

11

Peer-Reviewed Publications (2021-2025)

03

Major Patents Pending

Intellectual Property

Diagnostic Innovation (Dx)

Functionalized Gold Nanoparticle Platform

Filing Status: Patent Pending (2024) | Institution: MCARS, Jamia Millia Islamia

This platform utilizes fluorescent gold nanoconjugates targeted at rapid diagnostic identification of enteric pathogens.

  • Conjugation with RecA protein for detection of DNA double-strand breaks.Conjugation with RecA protein for detection of DNA double-strand breaks.
  • Eliminates the need for genetic manipulation (GFP/RFP).
Therapeutic Application (Tx)

Engineered Lytic Phage Cocktails

Filing Status: Patent Pending (2021) | Lead: Joshi TxDx Lab

Foundation IP establishing a biological therapeutic library to combat "superbugs."

  • Library targeting the ESKAPE pathogen group.
  • Optimized cocktail formulations for high lytic efficiency.
  • Prevention of secondary bacterial resistance.

Journal Highlights

Our patented technologies are supported by rigorous academic investigations published in high-impact international journals.

Translational Microbiology

Synergistic Neutralization of AMR Pathogens: A Phage-Nanoconjugate Approach (2023)

Investigating the combined therapeutic efficacy of engineered phages and functionalized gold nanoparticles to neutralize antibiotic-resistant bacteria more effectively than mono-therapies.

Molecular Genetics

Resilience Mechanisms in Genomic Integrity: Deciphering DNA Repair in E. coli (2022)

Exploring how chromosomal cohesion promotes high-fidelity DNA double-strand break repair, providing fundamental insights into limiting pathogen evolution.

Supported by India's Premier Scientific Agencies

DSTDBTICMRSERB

Research led by Dr. Mohan C. Joshi and supported by the Wellcome Trust/DBT India Alliance.